Literature DB >> 12882771

Uveal melanoma survival in Sweden from 1960 to 1998.

Louise Bergman1, Stefan Seregard, Bo Nilsson, Göran Lundell, Ulrik Ringborg, Boel Ragnarsson-Olding.   

Abstract

PURPOSE: To investigate the crude and relative survival rates in patients with uveal melanoma in Sweden during the period from 1960 to 1998.
METHODS: A population-based national survey revealed 2997 cases of uveal melanoma in the Swedish Cancer Registry. The survival rates were calculated by the Hakulinen life-table method, using relative survival as an estimate for deaths due to uveal melanoma. The excess mortality rates were calculated with confidence intervals for the first 15 years after diagnosis. Multivariate regression analysis was undertaken to evaluate the influence of gender, age, and calendar period on relative survival the first 5 years after diagnosis. The underlying causes of deaths in the patients with uveal melanoma, as found in the Cause of Death Registry were also investigated.
RESULTS: Up to December 31, 1998, 2003 patients had died. The 5-year crude survival rate was 60.3% and the relative survival 70.1%. After 10 years, the rates were 42.5% and 59.4%, respectively. Significant excess mortality existed up to 5.5 years after diagnosis. In the multivariate model, younger age (P < 0.001) and later calendar period (P = 0.002), but not gender (P = 0.117), were associated with better relative survival. Deaths due to uveal melanoma were misclassified in the Cause of Death Registry in more than half of the cases.
CONCLUSIONS: This study, covering more than 95% of the uveal melanoma cases in the Swedish population revealed an improvement in relative survival rates for patients with uveal melanoma over time and a significant excess mortality up to 5.5 years after diagnosis.

Entities:  

Mesh:

Year:  2003        PMID: 12882771     DOI: 10.1167/iovs.03-0081

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  20 in total

Review 1.  The Zimmerman-McLean-Foster hypothesis: 25 years later.

Authors:  A D Singh; I G Rennie; T Kivela; S Seregard; H Grossniklaus
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma.

Authors:  Anne Marie Lane; Ivana K Kim; Evangelos S Gragoudas
Journal:  JAMA Ophthalmol       Date:  2018-09-01       Impact factor: 7.389

Review 3.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

Review 4.  Disparities in Uveal Melanoma: Patient Characteristics.

Authors:  Erin E Nichols; Ann Richmond; Anthony B Daniels
Journal:  Semin Ophthalmol       Date:  2016-04-29       Impact factor: 1.975

5.  No Gender Differences in Long-Term Survival after Brachytherapy of 1,541 Patients with Uveal Melanoma.

Authors:  Gustav Stålhammar; Thonnie Rose See; Maria Filì; Stefan Seregard
Journal:  Ocul Oncol Pathol       Date:  2019-03-19

6.  Five Decades of Enucleations for Uveal Melanoma in One Center: More Tumors with High Risk Factors, No Improvement in Survival over Time.

Authors:  Christine D M Roelofsen; Annemijn P A Wierenga; Sjoerd van Duinen; Robert M Verdijk; Jaco Bleeker; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager
Journal:  Ocul Oncol Pathol       Date:  2020-12-15

7.  Uveal melanoma: Long-term survival.

Authors:  Tomas Radivoyevitch; Emily C Zabor; Arun D Singh
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

8.  Assessment of the effect of iris colour and having children on 5-year risk of death after diagnosis of uveal melanoma: a follow-up study.

Authors:  Andrea Schmidt-Pokrzywniak; Sven Kalbitz; Oliver Kuss; Karl-Heinz Jöckel; Norbert Bornfeld; Andreas Stang
Journal:  BMC Ophthalmol       Date:  2014-04-01       Impact factor: 2.209

9.  Bevacizumab and intraocular tumors: an intriguing paradox.

Authors:  Mariam el Filali; Long V Ly; Gregorius P M Luyten; Mieke Versluis; Hans E Grossniklaus; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2012-10-05       Impact factor: 2.367

10.  Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth.

Authors:  Mariam El Filali; Irene Homminga; Willem Maat; Pieter A van der Velden; Martine J Jager
Journal:  Mol Vis       Date:  2008-09-24       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.